# Artemether + lumefantrine

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

EMLc | ATC codes: P01BF01

| | |
|---|---|
| **Indication** | Malaria due to Plasmodium vivax ICD11 code: 1F41 |
| **INN** | Artemether + lumefantrine |
| **Medicine type** | Chemical agent |
| **List type** | Core |
| **Formulations** | **Oral > Solid > dispersible tablet:** 20 mg + 120 mg (EMLc)<br>**Oral > Solid > tablet:** 20 mg + 120 mg |
| **EML status history** | First added in 2002 (TRS 914)<br>Changed in 2007 (TRS 946)<br>Changed in 2007 (TRS 950)<br>Changed in 2009 (TRS 958)<br>Changed in 2025 (TRS 1064) |
| **Sex** | All |
| **Age** | Also recommended for children |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Wikipedia** | Artemether + lumefantrine |
| **DrugBank** | Artemether,<br>Lumefantrine |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to remove the footnotes describing a weight restriction and use during pregnancy, noting that use of this medicine should be in accordance with recommendations in WHO malaria guidelines.